About us
About Redenlab
Management team
Advisory board
Partners
What we do
Indications
Ataxia
Huntington’s Disease (HD)
Parkinson’s Disease
Alertness, Fatigue and Stress (AFS)
Frontotemporal Dementia (FTD)
Amyotrophic lateral sclerosis (ALS) / Motor Neurone Disease (MND)
Our technology
News & Publications
News
Events
Publications
Employment opportunities
Clinical Trial Solutions
Virtual trials
Redenlab’s recording solutions
Protocol design and development
Data analysis and interpretation
Quality control and assurance
Project management
Contact Us
Redenlab awarded $2.5M to scale AI-driven speech biomarkers for dementia detection →
About us
About Redenlab
Management team
Advisory board
Partners
What we do
Indications
Ataxia
Huntington’s Disease (HD)
Parkinson’s Disease
Alertness, Fatigue and Stress (AFS)
Frontotemporal Dementia (FTD)
Amyotrophic lateral sclerosis (ALS) / Motor Neurone Disease (MND)
Our technology
News & Publications
News
Events
Publications
Employment opportunities
Clinical Trial Solutions
Virtual trials
Redenlab’s recording solutions
Protocol design and development
Data analysis and interpretation
Quality control and assurance
Project management
Contact Us
Artificial intelligence
×
×